HeartFlow Analysis

The HeartFlow Analysis is an AI-based software device that processes patient-specific CT scan data to create a 3D model of the coronary arteries and simulate blood flow, providing non-invasive FFRct values and plaque characterization. Its purpose is to aid clinicians in the risk assessment, functional evaluation, and treatment planning of coronary artery disease by offering detailed anatomical and physiological insights derived from deep learning algorithms.

The HeartFlow Analysis is an AI-driven software medical device designed for the non-invasive quantitative and qualitative assessment of coronary artery disease (CAD) in patients with suspected CAD. It utilizes previously acquired Computed Tomography (CT) DICOM data to generate a comprehensive analysis. The software employs deep learning algorithms, trained since 2015 on extensive CT datasets, to automatically extract anatomical data, identify and characterize plaque, and create a 3D model of the patient's coronary arteries from static CT images. Key functionalities include centerline detection, lumen boundary determination, the ability to model stenosis and plaque, and features like 'PreRead' for anatomy extraction and 'Planner' for modifying the anatomical model. From the 3D model, HeartFlow Analysis performs coronary physiological simulations to compute FFRct (Fractional Flow Reserve derived from CT). This involves calculating simulated pressure, velocity, and blood flow, providing hemodynamic information that, alongside anatomical details like percent stenosis and plaque volumes, aids in functional evaluation. The outputs, presented as graphics and text accessible via an internet-connected device, are intended to support qualified clinicians in risk stratification, diagnosis, and treatment planning for CAD. The system allows for clinician review and assessment of the analysis, which is meant to be used as a supplemental diagnostic aid in conjunction with other clinical information and professional judgment. Validation studies, including stress and repeatability testing using previously acquired diagnostic images, have indicated the device's acceptability for its intended use.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the AI algorithm's performance in plaque characterization and FFRct calculation compare to invasive FFR measurements across diverse patient populations and varying degrees of stenosis severity?; What specific deep learning architectures are employed, and how is the continuous learning from new CT data and studies managed to ensure algorithm robustness and prevent drift without compromising previously validated performance?; Can the HeartFlow Analysis differentiate between stable and vulnerable plaque characteristics, and if so, what is the validation data supporting this capability?; What is the impact of CT image quality variability (e.g., motion artifacts, calcium blooming) on the accuracy of the 3D model generation and subsequent FFRct values, and what are the quality control thresholds for input data?; How does the 'Planner' feature, which allows modification of the anatomic model to remove luminal narrowings, guide or predict outcomes of potential revascularization strategies, and what is its validated accuracy in such predictive modeling?